Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT) today announced that two separate pre-clinical studies on animalsof the company's PLacental eXpanded (PLX) cell therapy demonstrated that it may be effective in treating both neuropathic and inflammatory nerve pain.
Pluristem conducted the trials in Germany with Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin.
In the trials, animals were induced with neuropathic pain by affecting the Sciatic nerve, or with inflammatory pain by an injection into the footpad. The administration of PLX cells, the sensitivity to thermal and mechanical stimuli in the animals was dramatically reduced correlated with the number of injected PLX cells.
Pluristem scientific advisory board chairman Dr. Edwin Horwitz said that the results position PLX cells as a promising candidate for a variety of clinical indications. Horwitz is president of the International Society for Cellular Therapy.
Pluristem's share price rose 7.3% in premarket trading today to $1.17, giving a market cap of $23 million. The share price fell 6% on Friday.
Published by Globes [online], Israel business news - www.globes-online.com - on August 9, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010